Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Adamis Pharmaceuticals' technology which constitutes its compound APC-100 received a Notice of Allowance for its patent application in Canada.
Subscribe to our email newsletter
APC-100 prevents the occurrence or recurrence of prostate cancer, the company claims.
The drug is an orally available anti-androgenic/anti-inflammatory, signal transduction inhibitor which is said to have high therapeutic activity.
Notice of Allowance, which is the final step in the issuance of a patent, is believed to enhance the company’s patent portfolio for the use of APC-100.
APC-100 is part of an ongoing Phase 1/2a clinical prostate study that began in August.